0000921114 false 0000921114 2022-03-30 2022-03-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, DC 20549






Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): March 30, 2022



(Exact name of Registrant as specified in its charter)


Washington 001-37544 91-1549568
(State or other jurisdiction of
incorporation or organization)
(Commission File Number) (IRS Employer Identification No.)


4503 Glencoe Avenue

Marina del Rey, California



(Address of principal executive offices) (Zip Code)


(310) 655-2928

(Registrant’s Telephone number)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
Common Stock   ARMP   NYSE American







Item 3.02 Unregistered Sales of Equity Securities.


As previously disclosed on our Current Report on Form 8-K filed with the U.S. Securities Exchange Commission, on February 9, 2022, Armata Pharmaceuticals, Inc. (NYSE: ARMP), a Washington corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, “Innoviva”), pursuant to which the Company agreed to issue and sell to Innoviva, in a private placement, up to 9,000,000 newly issued shares of common stock, par value $0.01 per share (“common stock”), of the Company (the “Shares”) and warrants (the “Common Warrants”) to purchase up to 4,500,000 shares of common stock, with an exercise price per share of $5.00 (the “Private Placement”). Each Share is sold together with one Common Warrant, and the per-unit purchase price is $5.00.


First Closing


The Private Placement occurred in two tranches. The first closing (the “First Closing”) occurred on February 9, 2022, at which time Innoviva purchased 3,614,792 Shares and Common Warrants to purchase up to 1,807,396 Shares, which was the maximum number of Shares and Common Warrants issuable to Innoviva in compliance with any and all applicable laws and without the requirement for the prior receipt of the stockholders’ approval under the listing requirements of the NYSE American, in exchange for an aggregate gross cash payment of approximately $6.1 million.


Second Closing


As described below under Item 5.07, on March 30, 2022, the Company received shareholder approval to authorize the Company to complete the second tranche of the Private Placement (the “Second Closing”). On March 31, 2022, the Company completed the Second Closing and issued to Innoviva 5,385,208 Shares and Common Warrants to purchase up to 2,692,604 Shares for an aggregate purchase price of approximately $26.9 million.


Item 5.07 Submission of Matters to a Vote of Security Holders.


The Company held a special meeting of its shareholders (the “Special Meeting”) on March 30, 2022, at 9:00 a.m. local time at the Company’s headquarters in Marina del Rey, California. As described in the proxy statement for the Special Meeting, the Special Meeting was held for the following purposes:


  1. To approve the Second Closing, which, combined with issuance of Shares at the First Closing, will result in the issuance of shares equal to 20% or more of the outstanding common stock of the Company for less than the greater of book or market value of the Company’s Common Stock, as required by and in accordance with NYSE American Company Guide Rule 713 (the “Private Placement Proposal”);


  2. To authorize the adjournment of the Special Meeting in order to permit the solicitation of additional proxies if there are not sufficient votes to approve Proposals 1 described above at the time of the Special Meeting; and


  3. To conduct any other business properly brought before the Special Meeting or any adjournment or postponement thereof.


The voting results for proposal 1 were as follows:


Proposal 1 — Approval of Private Placement Proposal:


Votes For  Votes Against  Abstentions  Broker Non-Votes
24,591,047  23,394  6,628  0


The votes cast in favor of the Private Placement Proposal constituted approximately 99.9% of the total votes of shares of common stock cast on such matter at the Special Meeting.





Item 8.01 Other Events.


On March 31, 2022, the Company issued a press release announcing the completion of the Second Closing. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.


Item 9.01 Financial Statements and Exhibits.


  (d) Exhibits.


99.1   Press Release, dated March 31, 2022.
104   Cover Page Interactive Data File (embedded within Inline XBRL document).







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: March 31, 2022 Armata Pharmaceuticals, Inc.
  By: /s/ Steve R. Martin
  Name: Steve R. Martin
  Title: Chief Financial Officer




EX-99.1 2 tm2211112d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1




Armata Pharmaceuticals Announces Closing of Second and Final Tranche of

$45 Million Private Placement with Innoviva


MARINA DEL REY, Calif., March 31, 2022 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that, following a vote in favor of the transaction by the Armata shareholders, the Company has completed the closing of the second and final tranche of the Company's $45 million private placement of its common stock with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (NASDAQ: INVA) (together, "Innoviva"). In connection with the second closing, Armata issued 5,385,208 common shares and 2,692,604 warrants with an exercise price of $5.00 per share, at a per unit price of $5.00 per unit, in exchange for gross proceeds of approximately $26.9 million. Approximately 99% of the Armata shares represented and voting at the special meeting of shareholders voted in favor of the transaction.


The Company and Innoviva closed an initial tranche of the investment on February 9, 2022, which raised gross proceeds of approximately $18.1 million through the issuance of 3,614,792 common shares and warrants to purchase an additional 1,807,396 common shares at a strike price of $5.00 per share.


As of March 31, 2022, and following the second closing, Armata has 36,112,299 shares outstanding and warrants exercisable for 21,147,229 shares of common stock.


Armata was represented in the transaction by Thompson Hine LLP, and Ladenburg Thalmann & Co. Inc. provided a fairness opinion.


Willkie Farr & Gallagher LLP represented Innoviva in the transaction.


In addition, Armata Pharmaceuticals, Inc. filed its Annual Report for the year ended December 31, 2021 on Form 10-K with the SEC on March 17, 2022. The audit opinion included in the Company's Form 10-K contains a going concern explanatory paragraph. This announcement is made pursuant to the disclosure requirements of NYSE American Company Guide Sections 401(h) and 610(b) and does not represent any change or amendment to the Company’s financial statements or to its Annual report on Form 10-K for the year ended December 31, 2021.


This release does not constitute an offer to sell or the solicitation of an offer to buy any security. The shares offered have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws and may not be offered or sold in the United States or any state thereof absent registration under the securities act and applicable state securities laws or an applicable exemption from registration requirements.


About Armata Pharmaceuticals, Inc.


Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.







Forward Looking Statements


This communication contains "forward-looking" statements, including, without limitation, statements related to Armata's bacteriophage development programs, Armata’s ability to set up or operate R&D and manufacturing facilities, Armata's ability to meet expected milestones, Armata's ability to be a leader in the development of phage-based therapeutics, and statements related to the timing and results of clinical trials, including the anticipated results of clinical trials of AP-PA02 and AP-SA02, and Armata's ability to develop new products based on bacteriophages and synthetic phages. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Armata's current expectations. Forward-looking statements involve risks and uncertainties. Armata's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the ability of Armata's lead clinical candidates, AP-PA02 and AP-SA02, to be more effective than previous candidates; Armata's ability to expedite development of AP-PA02; Armata's ability to advance its preclinical and clinical programs and the uncertain and time-consuming regulatory approval process; Armata's ability to develop products based on bacteriophages and synthetic phages to kill bacterial pathogens; the Company's expected market opportunity for its products; Armata's ability to sufficiently fund its operations as expected, including obtaining additional funding as needed; and any delays or adverse events within, or outside of, Armata's control, caused by the ongoing COVID-19 pandemic. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the SEC, including in Armata's Annual Report on Form 10-K, filed with the SEC on March 17, 2022, and in its subsequent filings with the SEC.


Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.



Media Contacts:


At Armata:

Steve Martin

Armata Pharmaceuticals, Inc.




Investor Relations:

Joyce Allaire

LifeSci Advisors, LLC






EX-101.SCH 3 armp-20220330.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 armp-20220330_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 armp-20220330_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Mar. 30, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 30, 2022
Entity File Number 001-37544
Entity Central Index Key 0000921114
Entity Tax Identification Number 91-1549568
Entity Incorporation, State or Country Code WA
Entity Address, Address Line One 4503 Glencoe Avenue
Entity Address, City or Town Marina del Rey
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90292
City Area Code 310
Local Phone Number 655-2928
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ARMP
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
XML 8 tm2211112d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000921114 2022-03-30 2022-03-30 iso4217:USD shares iso4217:USD shares 0000921114 false 8-K 2022-03-30 ARMATA PHARMACEUTICALS, INC. WA 001-37544 91-1549568 4503 Glencoe Avenue Marina del Rey CA 90292 310 655-2928 false false false false false Common Stock ARMP NYSEAMER EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://armatapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2211112d1_8k.htm armp-20220330.xsd armp-20220330_lab.xml armp-20220330_pre.xml tm2211112d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2211112d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2211112d1_8k.htm" ] }, "labelLink": { "local": [ "armp-20220330_lab.xml" ] }, "presentationLink": { "local": [ "armp-20220330_pre.xml" ] }, "schema": { "local": [ "armp-20220330.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "armp", "nsuri": "http://armatapharma.com/20220330", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2211112d1_8k.htm", "contextRef": "From2022-03-30to2022-03-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://armatapharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2211112d1_8k.htm", "contextRef": "From2022-03-30to2022-03-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-041005-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-041005-xbrl.zip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